Skip to main content

Market Overview

Vascular Biogenics' Ovarian Cancer Gene Therapy Shows Response Rate Of Over 58%

  • Vascular Biogenics Ltd (NASDAQ: VBLTannounced positive results of the pre-specified interim analysis of the Phase 3 OVAL study of VB-111 (ofranergene obadenovec) in recurrent platinum-resistant ovarian cancer.
  • VB-111 (ofranergene obadenovec) is an anti-cancer gene-therapy.
  • The data was published online in Gynecologic Oncology.
  • The analysis showed a CA-125 (validated biomarker) response rate of 58% or higher in evaluable patients in the VB-111 treatment arm.
  • In patients who had a post-dosing fever, a marker for VB-111 treatment, the response rate was 69%.
  • Recently an independent Data Safety Monitoring Committee found no safety issues with the Phase 3 trial and recommended its continuation.
  • Price Action: VBLT shares are trading higher by 7.6% at $1.98 in premarket trading on the last check Thursday.

Related Articles (VBLT)

View Comments and Join the Discussion!

Posted-In: Ovarian Cancer Phase 3Biotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at